Phathom Pharmaceuticals Inc’s recent filing unveils that its CFO and CBO Henderson Molly unloaded Company’s shares for reported $38128.0 on Apr 08 ’24. In the deal valued at $11.10 per share,3,435 shares were sold. As a result of this transaction, Henderson Molly now holds 95,263 shares worth roughly $0.85 million.
Then, Curran Terrie sold 16,851 shares, generating $153,513 in total proceeds. Upon selling the shares at $9.11, the President and Chief Executive now owns 410,784 shares.
Before that, TAKEDA PHARMACEUTICAL CO LTD sold 3,703,703 shares. Phathom Pharmaceuticals Inc shares valued at $29,999,994 were divested by the 10% Owner at a price of $8.10 per share. As a result of the transaction, TAKEDA PHARMACEUTICAL CO LTD now holds 3,755,583 shares, worth roughly $33.69 million.
Needham reiterated its Phathom Pharmaceuticals Inc [PHAT] rating to a Buy in a research note published on January 05, 2024; the price target was $26. A number of analysts have revised their coverage, including H.C. Wainwright’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating. Evercore ISI also remained covering PHAT and has increased its forecast on May 11, 2023 with a “an Outperform” recommendation from previously “an In-line” rating. Craig Hallum started covering the stock on March 13, 2023. It rated PHAT as “a Buy”.
Price Performance Review of PHAT
On Friday, Phathom Pharmaceuticals Inc [NASDAQ:PHAT] saw its stock fall -5.38% to $8.97. Over the last five days, the stock has lost -11.54%. Phathom Pharmaceuticals Inc shares have fallen nearly -1.75% since the year began. Nevertheless, the stocks have fallen -16.32% over the past one year. While a 52-week high of $17.02 was reached on 04/09/24, a 52-week low of $6.07 was recorded on 02/13/24. SMA at 50 days reached $9.52, while 200 days put it at $10.27. A total of 0.59 million shares were traded, compared to the trading of 0.42 million shares in the previous session.
Levels Of Support And Resistance For PHAT Stock
The 24-hour chart illustrates a support level at 8.63, which if violated will result in even more drops to 8.28. On the upside, there is a resistance level at 9.60. A further resistance level may holdings at 10.22. The Relative Strength Index (RSI) on the 14-day chart is 40.65, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.97, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 98.21%. Stochastics %K at 4.01% indicates the stock is a buying.
The most recent change occurred on October 21, 2022 when Jefferies began covering the stock and recommended ‘”a Buy”‘ rating along with a $16 price target.
